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 Abstract 
 
Objective: The objective of this selective EBM review is to determine whether or not there is 
efficacy with combination treatment benzoyl peroxide and clindamycin for progressive macular 
hypomelanosis in adults. 
 
Study Design: A review of three English language studies. One published in 2006 and two in 
2011. Includes two RCT’s and one randomized left-right comparison study. 
   
Data Sources: Researched articles via PubMed and Cochrane database. All articles were 
published in peer-reviewed journals. Two randomized, controlled trials and one randomized left-
right comparison study were used.  
 
Outcomes Measured: The outcomes measured by: subjective patient ratings based on 
photographs before and after treatment and two dermatologists’ ratings. Relyveld et al study and 
Sim et al study in addition used a color analyzer. 
 
Results: The two randomized, controlled trials and the left-right comparison study showed that 
the use of clindamycin and benzoyl peroxide was effective in the treatment of progressive 
macular hypomelonosis in adults. Results from these three studies showed Improvement of the 
overall PMH lesions by the investigator, patient, dermatologist and color analyzer (quantitatively 
compares discoloration, erythema, pigmentation and skin color). 
 
Conclusions: The results of the randomized, controlled trials and left-right comparison study 
indicate that combination products clindamycin and benzoyl peroxide are effective in the 
treatment of progressive macular hypomelonosis. All three studies also demonstrated that 
benzoyl peroxide and clindamycin were safe when used to treat PMH. 
. 
Key Words: progressive macular hypomelanosis; clindamycin, benzoyl peroxide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Colosi, Benzoyl Peroxide & Clindamycin PMH, 1 
 
Introduction 
Progressive macular hypomelanosis (PMH) is a dermatosis characterized by nummular, 
hypopigmented, symmetric, asymptomatic macules of unclear etiology which affect the front and 
back of the trunk and are confluent around the midline.
3
 The lesions are not preceded by 
inflammatory disease and tend to increase progressively in number. Histopathologically, the skin 
lesions show a decrease in melanin content in the epidermis compared with the adjacent skin 
without lesions. No other abnormalities are seen in the epidermis or dermis such as spongiosis or 
other signs of eczematous inflammation.
4
 There is no consensus or first-line therapy in the 
treatment of PMH and the treatment options used are very little effective.
3
 
 PMH has been reported in patients with skin type’s I-III.2 It occurs in all races and has a 
worldwide distribution, but it is more frequently identified in young adults/women and African 
American people from tropical countries, but the prevalence studies are scarce.
3
 In 1994, Lesueur 
et al diagnosed 121 cases of PMH during a screening for leprosy among 511 patients in the 
French West Indies (Martinique). Also in Martinique, Guillet et al diagnosed 150 new cases in 
their dermatology clinic.
2
 PMH can cause cosmetic problems for patients, which can lead to a 
negative impact on the patient’s quality of life. Since, this condition is frequently misdiagnosed; 
no exact percentage is given to determine how much money is spent annually.
1
 However, due to 
the numerous individuals affected by progressive macular hypomelanosis, this condition is 
commonly encountered in the scope of PA practice. Therefore, it is important to be able to 
correctly diagnose and treat PMH. 
The diagnosis is clinical and the main differential diagnosis is pityriasis versicolor.
3
 To 
differentiate pityriasis versicolor from PMH potassium hydroxide test results of epidermal 
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scrapings are performed.
2
 The clinical findings of PMH include the presence of red follicular 
fluorescence in the hypopigmented spots when illuminated with a wood’s lamp in a dark room.2 
Unfortunately, little is known about the origin and pathogenesis of PMH. 
2
 One thought is 
the presence of propionibacterium acnes (P. acnes) in the hypopigmented macules playing an 
important role in the development of PMH. Similar to the Malassezia species in tines versicolor, 
it is possible that P. acnes produces a depigmenting factor that disrupts melanogenesis and 
induces hypopigmented lesions. Since a bacteria may contribute to the cause of PMH it makes 
sense that antimicrobial therapy would be used for the treatment of PMH and has been associated 
with clinical improvement.
4
 
Numerous therapy options have been used with variable results for the treatment of PMH, 
including local hydration, sun exposure with UVA/UVB, phototherapy, topical corticosteroids 
and oral tetracycline. However, there is no first-line medication or consensus in the treatment of 
this dermatosis and the treatment options used have shown to be not very effective. However, the 
combination of benzoyl peroxide 5% and clindamycin 1% has shown to be quite effective 
against P. acnes as previously mentioned. The combined use of both of these products reduces 
the risk of development of resistant P. acnes. Elimination of P. acnes with a topical antimicrobial 
therapy could therefore improve repigmentation in patients with PMH.
3
  
Objective 
“The objective of this selective EBM review is to determine whether or not there is 
efficacy with combination treatment benzoyl peroxide and clindamycin for progressive macular 
hypomelanosis in adults.” 
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Methods 
The population in these studies consisted of healthy men and women over the age of 
twenty-one with a diagnosis of PMH. The interventions used were 5% benzoyl peroxide and 1% 
clindamycin. The treatment groups receiving benzoyl peroxide and clindamycin were compared 
to those receiving either UVA/fluticasone 0.05%, gel placebo, or narrow band ultraviolet B 
(NBUVB). The outcomes measured were those of patient-oriented evidence. There was 
improvement of the overall PMH lesions by the investigator, patient, dermatologist and color 
analyzer (quantitatively compares erythema, pigmentation and skin color). This review includes 
two randomized control trials and one randomized left-right comparison study. 
 The three studies in this review were researched using PubMed and Cochrane database 
by the author. Keywords used in literature search were “progressive macular hypomelanosis”, 
“clindamycin”, and “benzoyl peroxide”. All articles were published in English in peer-reviewed 
journals. One article was published in 2006 and the other two articles in 2011. Articles were 
selected by the author based on their relevance and outcome to the patient. All three reviews had 
similar inclusion and exclusion criteria. The Inclusion criteria were healthy men and women over 
21 years old with a diagnosis of PMH. The exclusion criteria were pregnant or lactating females, 
allergies to products given or history of pityriasis versicolor. Table 1 demonstrates the 
demographics of the studies included. Statistics included in the studies were relative benefit 
increase (RBI), absolute benefit increase (ABI), relative risk increase (RRI), absolute risk 
increase (ARI), number needed to treat (NNT), number needed to harm (NNH), and p-values. 
Table 1: Table of demographics and characteristics of included studies 
Study  Type  # 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria  
W/D Interventions 
Relyveld
2006 (2) 
RCT 45 16-
55 
Ages 16-55 
with 
Positive 
potassium 
7 Benzoyl 
peroxide 5% 
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diagnosis of 
PMH 
hydroxide test 
results; 
sensitive to any 
of the study 
medication 
ingredients, 
pregnant or 
lactating 
hydrogel & 
clindamycin 1% 
lotion & UVA 
VS. Fluticasone 
& UVA 
Santos, 
2011 (3) 
RCT (double 
blind 
placebo 
controlled) 
23 >15 >15, clinical 
diagnosis of 
PMH 
confirmed by 
two 
dermatologists
, negative 
mycological 
examination 
& no 
previous 
treatment for 
30 days 
Pregnant or 
lactating 
females, 
patients with 
associated 
disease & 
patients allergic 
to the therapy 
drugs used in 
this study or 
sensitive to 
sunlight 
0 Benzoyl 
peroxide 5% & 
Clindamycin 
1% VS. 
Visually 
matched 
placebo 
Sim, 
2011 (4) 
Randomized 
left-right 
comparison 
study 
10 21-
43 
Ages 21-43, 
with a 
diagnosis of 
PMH  
History of 
pityriasis 
versicolor or 
other 
inflammatory 
disorders in the 
hypopigmented 
spot, sensitive 
to any 
ingredients of 
the study 
medications or 
sunlight, treated 
with other 
treatments, 
pregnant or 
lactating 
females 
3 NBUVB with 
benzoyl 
peroxide  & 
clindamycin VS. 
NBUVB 
monotherapy 
 
Outcomes Measured 
Outcomes measured were those of patient-oriented evidence that matters. All three 
articles measured the efficacy of repigmentation/decrease incidence of hypopigmentation of 
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PMH by subjective patient ratings (based on photographs taken before and after treatment) and 
by two dermatologists. The differences between these studies are the Relyveld et al study also 
measured the skin with a color analyzer at baseline; after 2, 6, 10, and 14 weeks of treatment; 
and after a period of 12 weeks without treatment (26 weeks). This color analyzer transforms a 
reflectance spectrum R (λ) into 3 values: L∗, a∗, and b∗. L∗ represents the lightness of the 
spectrum and varies from 0 for a black object to 100 for a white object, a∗ represents green 
(negative values) and red (positive values), and b∗ represents blue (negative values) and yellow 
(positive values).
2
 Santos et al measured efficacy on photographs, but they were taken on day’s 
0, 15, 60 and 90. The following scale of clinical improvement was previously established based 
on the area of repigmentation: no improvement, little improvement, partial improvement, 
significant improvement, and complete recovery.
3
 Lastly, Sim et al study in addition to using the 
photographs, also used the color analyzer. This study rated the efficacy of repigmentation on a 
score from 0-4; 0-5%, no change; 1, 6-25% repigmentation; 2, 26-50% repigmentation; 3, 51-
75% repigmentation; 4, 76-100% repigmentation.
4
  
 Another outcome measured was adverse events of benzoyl peroxide and clindamycin. 
This was evaluated by the side effects and physical examination findings. Though there were 
some effects documented, this never deterred patients from using the medication or caused them 
to not follow-up. 
Results 
This EBM review was done on two randomized controlled trials and one randomized left-
right comparison study.  The results of the two randomized controlled trials were presented as 
dichotomous data; therefore, I will display the results of those two studies together in Tables 2 
& 3 and the left-right comparison study separate. Data from the two dichotomous studies were 
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analyzed with the intention to treat.                                                                                                                                
 In the Relyveld et al study, after fourteen weeks of treatment, both the treated sides 
became darker than normal skin, but this effect was more pronounced on the bcUVA (benzoyl 
peroxide/clindamycin + UVA) side. After twelve weeks without treatment, the antibacterial 
(bcUVA)-treated side had the same degree of pigmentation as normal skin whereas the anti-
inflammatory fUVA (fluticasone + UVA)-treated side was lighter than normal skin. Although 
the skin on the bcUVA side remained evenly pigmented, hypopigmentation macules reappeared 
on the fUVA side. The patients and dermatologists scored the bcUVA-treated side higher than 
the fUVA-treated side. This difference was highly significant after fourteen weeks of treatment 
(P < .0001 for patients, P < .0001 for dermatologists). At the end of the follow-up, 62% of the 
patients judged their bcUVA-treated side as totally repigmented, but only 13% of the patients 
gave such a score to their fUVA-treated side (P < .0001). The dermatologists scored 62% of the 
bcUVA-treated sides and 22% of fUVA-treated sides as totally repigmented at the end of the 
follow-up (P < .0001).  Most adverse effects were mild and followed anticipated patterns. More 
patients reported cutaneous side effects with antibacterial than with corticosteroid therapy (71% 
vs. 24%, P < .0001). The incidence of side effects decreased after the second week of both 
treatments. After the sixth week, only four (9%) patients mentioned side effects on the bcUVA 
side and three (7%) patients mentioned side effects on the fUVA side.
2
 Unfortunately, the study 
did not list what the exact side effects were, therefore, it is not documented in this paper.  
 In the Santos et al study patients were divided into two groups. Group A used the topical 
combination of benzoyl peroxide 5% and clindamycin 1% and group B used gel cream as 
placebo. Patients were advised to expose themselves to the sun on daily basis and were 
systematically evaluated and photographed. The collected data was entered and analyzed. A p 
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value < 0.05 was considered statistically significant. Eleven patients (85%) in group A showed 
significant improvement of lesions and only two patients (20%) in group B showed equivalent 
clinical improvement, with a statistically significant difference between the two groups, p = 
0.003. Seven patients, (53%) in group A, showed complete recovery of lesions 90 days after 
beginning the therapy and only two patients (20%) in group B were cured at the same time 
interval. Thirteen patients (56%) had at least one side effect during treatment, eleven (85%) 
patients from group A, and two (15%) from group B, with a statistically significant difference 
between the two groups (p = 0.003). The clinical side effects reported were pruritus (50%), 
stinging (40%), erythema (30%), desquamation (22%), burning sensation (22%), xeroderma 
(8%) and plaques (4%). The side effects were well tolerated by all patients and there was no loss 
in terms of follow-up.
3
 Table 2 shows the efficacy of benzoyl peroxide 5% and clindamycin 1% 
in the treatment of progressive macular hypomelanosis in the two studies just discussed. Table 3 
shows the incidence of side effects in patients treated with benzoyl peroxide and clindamycin 
versus the control fUVA for Relyveld et al study or placebo for Santos et al study. 
Table 2 Clinical efficacy of benzoyl peroxide and clindamycin in the treatment of PMH 
 
Study  CER 
(fUVA) for 
Relyveld, 
(placebo) for 
Santos 
EER 
benzoyl 
peroxide 5% 
+ 
clindamycin 
1%  
p-value RBI ABI NNT 
Relyveld, 
2006 
22% 62% P < .0001 180% 40% 3  
Santos, 2011 20% 85% P < 0.003 330% 65% 2 
 
CER – control event rate, EER – experimental event rate, RBI – relative benefit increase, 
ABI – absolute benefit increase, NNT – number needed to treat 
Table 3 Incidence of side effects in patients treated with benzoyl peroxide & clindamycin vs. control 
Study CER (fUVA) 
for Relyveld, 
(placebo) for 
EER 
benzoyl 
peroxide 5% + 
RRI ARI NNH 
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Santos clindamycin 1% 
Relyveld, 2006 24% 71% 200% 47% 3 
Santos, 2011 15% 85% 470% 70% 2 
 
EER – experimental event rate, CER – control event rate, RRI – relative risk increase, 
ARI – absolute risk increase, NNH – number needed to harm 
 Lastly, I will discuss the Sim et al study which since it was not presented in dichotomous 
data; I will discuss the results narratively. After 8 weeks of treatment, significant repigmentation 
appeared at both of the treated sides compared with the initial evaluation. The mean difference in 
L values between the skin lesions and adjacent skin without lesions was 4.52 ± 1.65 at the initial 
evaluation and was reduced significantly to 0.94 ± 0.65 during the treatment period in the comb-
NBUVB area (benzoyl peroxide & clindamycin + UVB), and in the mono-NBUVB (UVB) area, 
it was 4.34 ± 1.39 and 1.18 ± 0.94 respectively (P < 0.05). However, there were no significant 
differences between each treated site at both of the evaluation points in time. At 6 months after 
treatment, clinical improvement remained in four of seven patients; however, almost recurrence 
occurred in the other patients. The mean difference in L values between the skin lesions and 
adjacent skin without lesions was 1.86 ± 1.42 in the comb-NBUVB area and 2.05 ± 1.55 in the 
mono-NBUVB area, and this difference was not statistically significant. There were minimal 
side effects in this study. Five patients complained of transient irritation and two patients 
complained of erythematous skin eruption in the comb-NBUVB area and this resolved following 
daily application of anti-microbial gel. All adverse effects were mild and resolved with topical 
corticosteroid therapy.
4
 
Discussion 
 In the Relyveld et al study, antibacterial therapy with UVA was more effective than anti-
inflammatory therapy with UVA in the treatment of PMH. Anti-bacterial therapy led to better 
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repigmentation as indicated by darker objective skin measurements and, more importantly, by 
higher score for treatment success by both patients and dermatologists.
2
 One limitation to this 
study or a recommendation I would suggest for the future would be a more thorough 
investigation on the medicines used. This study did not explore the optimal dose for benzoyl 
peroxide and clindamycin, other routes of administration, or whether other types of antibiotics 
are equally effective.  
 In the Santos et al study, the use of topical combination of benzoyl peroxide 5% and 
clindamycin 1% showed improvement in PMH. Patient adherence to regular sun exposure was 
similar between the two groups, which excludes the possibility of solar radiation being the main 
factor responsible for treatment success. The choice of the antimicrobial was due to the fact that 
combination of benzoyl peroxide 5% and clindamycin 1% are very effective against P. acne, 
easy to apply and has few systemic side effects. The main limitations of this study were small 
sample size and absence of confirmation of P. acnes. P. acnes was not objectively demonstrated 
in the lesions, but the significant clinical improvement of the group treated with benzoyl 
peroxide 5% and clindamycin 1% suggests colonization and supports the hypothesis that 
colonization by P. acnes may be involved in the pathogenesis of PMH.
3
 
 In the Sim et al study the comb-NBUVB treatment was not superior to mono-NBUVB 
treatment in patients with PMH. Even though both treatments showed improvement in 
repigmentation after eight weeks, there was no significant difference to determine which 
treatment was more effective. At the six month follow-up recurrence occurred in some 
participants. Even though recurrence occurred in some patients, NBUVB combined with benzoyl 
peroxide and clindamycin appears to be a safe and useful modality for the treatment of PMH. 
One limitation was the study did not have enough statistical power to support the equivalent 
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clinical results between the treated sites at both evaluation points in time because of the small 
number of enrolled patients. Therefore, further investigation with a larger number would be 
needed for relevant results.
4
 
Conclusion  
The trials reviewed imply that benzoyl peroxide 5% and clindamycin 1% is safe and 
effective for the treatment of progressive macular hypomelanosis. Patients in all three studies 
showed improvement in their PMH when applying topical benzoyl peroxide and clindamycin. It 
was also suggested from these studies that benzoyl peroxide and clindamycin are well-tolerated, 
as it does not cause significant adverse events. Benzoyl peroxide and clindamycin combination 
treatment provides a new treatment option for medical providers and those diagnosed with PMH. 
Although these studies do conclude the use of benzoyl peroxide and clindamycin are safe and 
effective, more trials should be done to assess the safety of using these two treatment options 
over a chronic time period, such as: exploring the optimal dose for benzoyl peroxide and 
clindamycin, other routes of administration or whether other types of antibiotics are equally 
effective. Regardless of the need for additional studies, benzoyl peroxide and clindamycin is a 
safe and effective way of treating progressive macular hypomelanosis.  
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